Stakeholders Offer Some Hatch-Waxman Creativity, Highlight Limits Of FDA Action
Other proposals were broad in nature, and did not provide the agency with specific mechanisms to consider.
Other proposals were broad in nature, and did not provide the agency with specific mechanisms to consider.